• Publications
  • Influence
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
BACKGROUND Visceral adipose tissue accumulates during antiretroviral therapy in many patients who are infected with the human immunodeficiency virus (HIV); this process is associated with anExpand
  • 161
  • 8
  • PDF
Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension
Background:HIV-infected patients receiving antiretroviral therapy often demonstrate excess visceral fat. A growth hormone-releasing factor, tesamorelin, may selectively reduce visceral fat in thisExpand
  • 60
  • 7
  • PDF
Delay in cART Initiation Results in Persistent Immune Dysregulation and Poor Recovery of T-Cell Phenotype Despite a Decade of Successful HIV Suppression
Background Successful combination antiretroviral therapy (cART) increases levels of CD4+ T-cells, however this increase may not accurately reflect long-term immune recovery since T-cell dysregulationExpand
  • 19
  • 5
  • PDF
Frailty in people aging with human immunodeficiency virus (HIV) infection.
The increasing life spans of people infected with human immunodeficiency virus (HIV) reflect enormous treatment successes and present new challenges related to aging. Even with suppression of viralExpand
  • 102
  • 4
  • PDF
Whey proteins as a food supplement in HIV-seropositive individuals.
On the basis of numerous animal experiments, a pilot study was undertaken to evaluate the effect of undenatured, biologically active, dietary whey protein in 3 HIV-seropositive individuals over aExpand
  • 66
  • 4
A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity
Objectives:Aging with HIV is associated with multisystem vulnerability that might be well characterized by frailty. We sought to construct a frailty index based on health deficit accumulation in aExpand
  • 99
  • 3
  • PDF
Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.
In recent years, a spectrum of metabolic and morphologic alterations has emerged among patients infected with human immunodeficiency virus (HIV) receiving antiretroviral treatment. Changes observedExpand
  • 61
  • 3
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
Objective:To investigate the effects of TH9507, a novel growth hormone releasing factor, on abdominal fat accumulation, metabolic and safety parameters in HIV-infected patients with central fatExpand
  • 73
  • 3
HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls
Background:Frailty is an age-related syndrome of decreased physiological reserve and resistance to stressors, associated with increased morbidity and mortality in the general elderly population. AnExpand
  • 71
  • 3
  • PDF
Aging with HIV vs. HIV Seroconversion at Older Age: A Diverse Population with Distinct Comorbidity Profiles
Objective People aging with HIV might have different health conditions compared with people who seroconverted at older ages. The study objective was to assess the prevalence of, and risk factors for,Expand
  • 70
  • 3
  • PDF